RhoVac AB is expanding its internationalpresence by attending conferences and by increasing activity on digital media
In alignment with company’s strategy to license or sell, whole or part of operations, following completion of the ongoing phase I/II clinical trial, RhoVac AB ("RhoVac") is attending business meetings at international conferences and is strengthening its online presence on digital media.Getting closer to reporting of RhoVac’s phase I/II clinical trial in Q2 2018, and in accordance with our strategy to find partners for further development of the company’s RV001 cancer vaccine, RhoVac has increased its international business development activities. Company’s management presented RhoVac at